Diabetes drug may protect the brain: canagliflozin tested for cognitive decline

NCT ID NCT07711171

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study investigates whether canagliflozin, a diabetes medication, can improve cognitive function in people with type 2 diabetes who also have mild cognitive impairment. The trial uses brain scans to measure changes in blood flow after insulin inhalation, along with standard cognitive tests. Participants take canagliflozin or another diabetes drug for six months to compare effects on brain health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
canagliflozin
What this could lead to
If successful, this could point toward a treatment that protects brain health in people with type 2 diabetes and early memory problems.
What could go wrong
This is a small, early-phase study with only 60 participants, so results may not apply widely. The cognitive benefits are uncertain and may not be clinically significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Fudan University affiliated Huadong Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.